Hallengren Mikael, Åstrand Per, Eksborg Staffan, Barle Hans, Frostell Claes
Department of Clinical Sciences, Division of Anaesthesia and Intensive Care, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.
Department of Clinical Sciences. Division of Internal Medicine, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.
PLoS One. 2017 Aug 24;12(8):e0183073. doi: 10.1371/journal.pone.0183073. eCollection 2017.
Septic shock is associated with high mortality. Aged and multimorbid patients are not always eligible for intensive care units. Norepinephrine is an accepted treatment for hypotension in septic shock. It is unknown whether norepinephrine has a place in treatment outside an intensive care unit and when given peripherally.
To describe mortality, Acute Physiology And Chronic Health Evaluation (APACHE-II), time to mean arterial pressure >65 mmHg, and adverse events in patients with septic shock receiving norepinephrine peripherally in an intermediate care unit.
From a retrospective chart review of 91 patients with septic shock treated with norepinephrine for hypotension, ward mortality, 30-, 60- and 90-day mortality, standardized mortality ratio (SMR) and adverse events (necrosis and arrhythmia) were analysed. Administration route via peripheral venous catheter or central venous catheter was registered.
Median age was 81 (43-96) years and median APACHE-II score was 26 (12-42). Observed ward mortality was 27.5% (SMR 0.443, 95% CI: 0.287-0.654), and 30-day and 90-day mortality were 47.2% and 58.2%, respectively.
Elderly patients with septic shock treated with norepinephrine displayed a better survival in the ward and at 30 days than expected. Our retrospective study did not indicate frequent complications when administering norepinephrine via a peripheral venous catheter.
感染性休克死亡率高。老年和患有多种疾病的患者不一定适合入住重症监护病房。去甲肾上腺素是治疗感染性休克低血压的一种公认疗法。目前尚不清楚去甲肾上腺素在重症监护病房以外的治疗中是否有一席之地,以及经外周给药时的情况。
描述在中级护理病房接受外周静脉注射去甲肾上腺素治疗的感染性休克患者的死亡率、急性生理与慢性健康状况评分系统(APACHE-II)、平均动脉压>65 mmHg的时间以及不良事件。
通过回顾性图表审查91例因低血压接受去甲肾上腺素治疗的感染性休克患者,分析病房死亡率、30天、60天和90天死亡率、标准化死亡率(SMR)以及不良事件(坏死和心律失常)。记录经外周静脉导管或中心静脉导管的给药途径。
中位年龄为81(43-96)岁,APACHE-II评分中位数为26(12-42)。观察到的病房死亡率为27.5%(SMR 0.443,95%CI:0.287-0.654),30天和90天死亡率分别为47.2%和58.2%。
接受去甲肾上腺素治疗的感染性休克老年患者在病房和30天时的生存率高于预期。我们的回顾性研究未表明经外周静脉导管给予去甲肾上腺素时会频繁出现并发症。